Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 1/20 | 0.50 |
| ▸ | LSS | P48449 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13157721 | 1.00 | GPR183 (0.50) | GPR183LSSHRH3SLC18A3HTR1A | |
| SCHEMBL3105384 | 0.95 | GPR183 (0.48) | GPR183LSSHRH3SLC18A3HTR1A | |
| SCHEMBL13157851 | 0.95 | GPR183 (0.48) | GPR183LSSHRH3SLC18A3HTR1A | |
| SCHEMBL13158155 | 0.92 | GPR183 (0.58) | GPR183LSSHRH3 | |
| SCHEMBL3099510 | 0.92 | GPR183 (0.58) | GPR183LSSHRH3 | |
| SCHEMBL13157665 | 0.92 | GPR183 (0.58) | GPR183LSSHRH3 | |
| SCHEMBL3099995 | 0.90 | GPR183 (0.47) | GPR183LSSHRH3SLC18A3HTR1A | |
| SCHEMBL13157846 | 0.90 | GPR183 (0.47) | GPR183LSSHRH3SLC18A3HTR1A | |
| SCHEMBL3093080 | 0.89 | GPR183 (0.47) | GPR183LSSHRH3SLC18A3HTR1A | |
| SCHEMBL13157769 | 0.89 | GPR183 (0.47) | GPR183LSSHRH3SLC18A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399455-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CXCR2 | GPR183 72/4885LSS 3057/4885HRH3 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.